U.S. markets open in 4 hours 6 minutes
  • S&P Futures

    3,852.75
    +43.50 (+1.14%)
     
  • Dow Futures

    31,226.00
    +314.00 (+1.02%)
     
  • Nasdaq Futures

    13,114.50
    +203.50 (+1.58%)
     
  • Russell 2000 Futures

    2,248.10
    +48.90 (+2.22%)
     
  • Crude Oil

    62.37
    +0.87 (+1.41%)
     
  • Gold

    1,744.40
    +15.60 (+0.90%)
     
  • Silver

    26.91
    +0.47 (+1.78%)
     
  • EUR/USD

    1.2044
    -0.0044 (-0.36%)
     
  • 10-Yr Bond

    1.4600
    0.0000 (0.00%)
     
  • Vix

    24.96
    -3.93 (-13.60%)
     
  • GBP/USD

    1.3950
    +0.0028 (+0.20%)
     
  • USD/JPY

    106.7130
    +0.2110 (+0.20%)
     
  • BTC-USD

    47,304.68
    +1,940.52 (+4.28%)
     
  • CMC Crypto 200

    950.22
    +17.08 (+1.83%)
     
  • FTSE 100

    6,594.11
    +110.68 (+1.71%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

Spruce Biosciences to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announced that the company will participate in the Credit Suisse 29th Annual Virtual Healthcare Conference.

Chief Executive Officer, Richard King, is scheduled to present on Thursday, November 12 at 4:15 p.m. EST.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.sprucebiosciences.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201104005055/en/

Contacts

Media
Will Zasadny
Canale Communications
(619) 961-8848
will.zasadny@canalecomm.com
media@sprucebiosciences.com

Investors
Thomas Hoffmann
Solebury Trout
(646) 378-2931
thoffmann@soleburytrout.com
investors@sprucebiosciences.com